FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Gutteridge Mike		 2. Date of Event Requiring Statement (MM/DD/YYYY)
2/15/2022 

 3. Issuer Name and Ticker or Trading Symbol

Apollo Endosurgery, Inc. [APEN]
(Last)        (First)        (Middle)

1120 SOUTH CAPITAL OF TEXAS HIGHWAY, BUILDING ONE, SUITE 300		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
VP, Int'l Sales and Marketing /
(Street)

AUSTIN, TX 78746      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
3/1/2022 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 22838 D  
Common Stock 21403 (1)D  
Common Stock 19796 (2)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (3)5/25/2027 Common Stock 14000.0 $6.5 D  
Stock Option (Right to Buy)  (4)12/7/2027 Common Stock 25500.0 $4.37 D  
Stock Option (Right to Buy)  (4)5/7/2029 Common Stock 22655.0 $3.49 D  
Stock Option (Right to Buy)  (5)5/7/2030 Common Stock 22171.0 $2.08 D  
Stock Option (Right to Buy)  (4)3/10/2031 Common Stock 14846.0 $5.95 D  
Explanation of Responses:
(1) Represents grants of Restricted Stock Units (the "RSU Awards") payable solely in common stock of the Issuer. The shares subject to the RSU Awards shall vest over a four-year period at the rate of 25% per year.
(2) Represents grants of "RSU Awards" payable solely in common stock of the Issuer. The shares subject to the RSU Awards shall vest over a three-year period at the rate of 33% per year.
(3) The shares underlying the performance based option vested 25% on 1/2/2018 and the remainder will vest in equal monthly installments over the following three years.
(4) The shares underlying the option shall vest as to 25% on the first anniversary of the grant date and the remainder will vest in equal monthly installments over the following three years.
(5) The shares underlying the option shall vest as to 33% on the first anniversary of the grant date and the remainder will vest in equal monthly installments over the following two years.

Remarks:
Corrected Table I breakout and footnotes, and corrected Table II footnotes.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Gutteridge Mike
1120 SOUTH CAPITAL OF TEXAS HIGHWAY
BUILDING ONE, SUITE 300
AUSTIN, TX 78746

VP, Int'l Sales and Marketing
Signatures
/s/ Brian Szymczak - Attorney-in-Fact3/10/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Apollo Endosurgery (NASDAQ:APEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Apollo Endosurgery Charts.
Apollo Endosurgery (NASDAQ:APEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Apollo Endosurgery Charts.